Roche Acquires Inflazome for ~$450M
Shots:
- Inflazome to receive $450.31M as up front and is eligible to receive additional contingent payments based on the achievement of certain predetermined milestones
- The acquisition allows the Roche to get full rights to Inflazome’s portfolio consisting of pre/ clinical orally available small molecule NLRP3 inhibitors
- Roche will further advance the NLRP3 inhibitors across a wide variety of indications targeting the unmet medical needs across a wide variety of inflammatory diseases
Click here to read full press release/ article | Ref: PRNewswire | Image: Ladder